HYDRAFIL® Presentation Receives Top Abstract Award at the 6th Annual American Society of Pain and Neuroscience Annual Meeting
17 Julio 2024 - 5:05AM
Business Wire
ReGelTec, Inc., announced that Dr. Douglas Beall received the
“Top Abstract Award” from the American Society of Pain and
Neuroscience (ASPN) for his presentation of the 3-Year follow-up
data on chronic low back pain patients treated with ReGelTec’s
HYDRAFIL System. The presentation was given to a packed room of
physicians at the 6th Annual meeting of ASPN in Miami, Florida. The
HYDRAFIL System allows doctors to treat chronic low back pain due
to degenerative disc disease with a hydrogel that can be melted and
implanted into a patient’s disc using a needle. The hydrogel
solidifies when it cools to body temperature providing cushioning,
restoring the natural biomechanics of the disc, and filling cracks
and fissures in annulus. The procedure is performed in an
outpatient setting with only local anesthesia.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240717721360/en/
Dr. Verrills presenting the Top Abstract
Award to Dr. Beall for his presentation on the clinical results of
the HYDRAFIL System out to three years in patients with chronic low
back pain due to degenerative disc disease. (Photo: Business
Wire)
“I am honored that my colleagues from ASPN choose my Abstract
reporting on the one, two, and three-year results obtained when
treating patients with the HYDRAFIL System as the Top Abstract at
the 6th Annual Meeting,” said Dr. Douglas Beall, Chief of
Interventional Spine Services, Comprehensive Specialty Care,
Edmond, Oklahoma. “The pain and functional improvements achieved
with the HYDRAFIL System in patients with chronic low back pain due
to degenerative disc disease are excellent and we cannot wait to
start the FDA Pivotal Study later this year.”
“We are extremely excited about the clinical results seen to
date in the first seventy-five patients treated with the HYDRAFIL
System and having Dr. Beall’s presentation win the Top Abstract
award is further validation of those results,” said Bill Niland,
the company’s co-founder and CEO. “We believe that the HYDRAFIL
System will transform the treatment of chronic low back pain due to
degenerative disc disease so receiving this recognition from the
interventional pain community is very rewarding and
motivating.”
ABOUT REGELTEC, INC:
ReGelTec, Inc. is a clinical stage medical device company
commercializing the HYDRAFIL® System, a percutaneous treatment for
chronic low back pain due to degenerative disc disease. The company
was formed when a team of chemical engineers with extensive
experience in polymer science partnered with a cross-functional
team of medical device professionals with multiple successful
exits. The HYDRAFIL System contains a hydrogel that can be injected
into a degenerated disc via a needle. Once approved, HYDRAFIL will
offer patients suffering from chronic back pain due to degenerative
disc disease a minimally invasive treatment option beyond
traditional conservative care. The HYDRAFIL System is an
investigational device, limited by United States law to
investigational use.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240717721360/en/
Peter Boyd (443) 451-3915 pboyd@regeltec.com